West Pharmaceutical's growth prospects are fueled by strong HVP demand, expanding biologics exposure and regulatory upgrades, despite near-term headwinds.
During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.
Eurizon Capital SGR S.p.A. boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 35.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 20,980 shares of the medical instruments supplier's stock after purchasing an additional 5,528 shares during the period. Eurizon
Candriam S.C.A. boosted its position in West Pharmaceutical Services, Inc. (NYSE: WST) by 3.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 99,489 shares of the medical instruments supplier's stock after purchasing an additional 3,140 shares during the quarter.
EXTON, Pa., Nov. 4, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 8:00 a.m. GMT in London, UK.
Bank Julius Baer and Co. Ltd Zurich increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 39.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,169 shares of the medical instruments supplier's stock after
West Pharmaceutical Services NYSE: WST reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1 therapies and biologics. The company raised its full-year revenue and adjusted earnings outlook following the quarter.